ZBH · 8-K · 20261104PR446145

Guidance / Outlook

ZIMMER BIOMET HOLDINGS, INC. · 2026-11-04 · Importance 62 · Surprise 68 · In source text

The company raised its 2026 organic constant-currency revenue-growth guidance to 3.0%–3.5% from 2.25%–3.25%, excluding the Paragon 28 acquisition impact through its April 2026 one-year anniversary. Updated constant-currency revenue-growth guidance is 4.1%–4.6%, compared with 3.4%–4.4% previously. Reported revenue growth guidance is now 4.4%–4.9%, versus 3.9%–4.9% previously, and the assumed foreign-exchange contribution was reduced from 0.5% to 0.25%. Adjusted diluted EPS guidance increased to $8.50–$8.60 from $8.47–$8.59.

Key facts

Zimmer Biomet updated its full-year 2026 reported revenue growth guidance to 4.4%–4.9%, from 3.9%–4.9%. source
Zimmer Biomet updated its full-year 2026 constant-currency revenue growth guidance to 4.1%–4.6%, from 3.4%–4.4%. source
Zimmer Biomet updated its full-year 2026 organic constant-currency revenue growth guidance to 3.0%–3.5%, from 2.25%–3.25%. source
Zimmer Biomet updated its full-year 2026 adjusted diluted EPS guidance to $8.50–$8.60, from $8.47–$8.59. source
The updated full-year 2026 organic constant-currency revenue growth guidance excludes the Paragon 28 acquisition impact through its one-year anniversary, approximately 110 basis points. source

Impact estimates

metric	direction	stage	expected	basis
revenue	positive	committed	+4.0%	Zimmer Biomet updated its full-year 2026 reported revenue growth guidance to 4.4%–4.9%, from 3.9%–4.9%.
revenue	positive	committed	+3.7%	Zimmer Biomet updated its full-year 2026 constant-currency revenue growth guidance to 4.1%–4.6%, from 3.4%–4.4%.
revenue	positive	committed	+2.8%	Zimmer Biomet updated its full-year 2026 organic constant-currency revenue growth guidance to 3.0%–3.5%, from 2.25%–3.25%.
net_income	positive	committed	—	Zimmer Biomet updated its full-year 2026 adjusted diluted EPS guidance to $8.50–$8.60, from $8.47–$8.59.